Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial

Documenti analoghi

• Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
  di: Jianli Zhao, et al.
  Pubblicazione: (2024)
• Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer
  di: Yihua Huang, et al.
  Pubblicazione: (2024)
• Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients
  di: Weili Xiong, et al.
  Pubblicazione: (2024)
• An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
  di: Jefferson Antonio Buendía
  Pubblicazione: (2013)
• Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
  di: Hiroji Iwata, et al.
  Pubblicazione: (2024)